Finch Therapeutics Group (FNCH) AI Stock Analysis

• Market Cap: $19.91M
• Dividend Yield: N/A
• Average Volume (3M): 1.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.99
• Revenue Growth: -100.00%
• EPS Growth: 89.80%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -8.82
• Shares Outstanding: 1,605,763
• 10 Day Avg. Volume: 1,737
• 30 Day Avg. Volume: 1,924
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 21.45
• Price to Cash Flow (P/CF): -1.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

The overall score reflects significant financial challenges, including persistent losses, high leverage, and negative cash flows. Technical analysis provides mixed signals, with some upward trends but weak momentum. Valuation indicators highlight risk due to negative earnings and lack of dividends.

Finch Therapeutics Group Business Overview & Revenue Model

Company Description

Finch Therapeutics Group (FNCH) is a clinical-stage biopharmaceutical company focused on developing novel microbiome therapies. The company operates in the biotechnology sector and is dedicated to harnessing the human microbiome to develop innovative treatments for a range of diseases, with a particular emphasis on gastrointestinal conditions, including recurrent Clostridium difficile infection (CDI). Finch Therapeutics employs a unique platform that leverages both its human-first discovery and machine learning capabilities to identify and develop microbiome-based therapies.

How the Company Makes Money

Finch Therapeutics Group makes money primarily through the development and commercialization of microbiome therapies. The company's revenue streams include research and development collaborations, partnerships, and grants. These partnerships often involve milestone payments and royalties related to the development and commercialization of microbiome therapeutics. Additionally, Finch Therapeutics may generate revenue through licensing agreements, where it licenses its proprietary technologies or therapeutic candidates to other companies in exchange for upfront payments, milestone payments, and royalties on sales. The company may also receive funding from institutional investors or government grants to support its research and development activities.

Finch Therapeutics Group Financial Statement Overview

Summary

Overall, Finch Therapeutics Group is facing financial difficulties, with persistent losses reflected in income statements, high leverage on the balance sheet, and negative cash flows. The company needs to address cost structures, improve revenue streams, and manage debt levels to enhance financial stability.

Income Statement

The income statement indicates significant challenges, with consistently negative net income and declining revenues. Gross profit margins are substantially negative, indicating cost issues relative to revenue generation. There is no evident revenue growth, and profitability metrics like EBIT and EBITDA margins are significantly negative.

Balance Sheet

The balance sheet shows a concerning financial position, with high total liabilities relative to equity, resulting in a negative equity in past years. The debt-to-equity ratio is high, indicating leveraged risk. However, stockholder equity has improved to a positive figure in recent years, suggesting some stabilization.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, indicating cash burn. Free cash flow growth is negative, reflecting declining cash generation ability. The operating cash flow to net income ratio is not favorable, underscoring inefficiencies in converting income into cash flow.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
2.85M	107.00K	861.00K	18.53M	7.72M	10.15M
	Gross Profit
2.71M	-7.09M	-4.65M	-38.75M	-25.43M	9.84M
	EBIT
-19.73M	-34.00M	-115.59M	-59.98M	-39.44M	-21.14M
	EBITDA
-19.51M	-32.48M	-82.69M	-57.68M	-38.65M	-20.66M
	Net Income Common Stockholders
-14.17M	-74.75M	-113.70M	-55.86M	-39.25M	-20.41M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
42.19M	25.12M	71.04M	133.48M	99.71M	42.19M
	Total Assets
0.00	55.37M	162.94M	225.37M	165.34M	103.57M
	Total Debt
0.00	30.13M	52.34M	6.01M	1.81M	143.15M
	Net Debt
42.19M	5.00M	-18.70M	-127.47M	-97.90M	100.96M
	Total Liabilities
0.00	32.49M	67.23M	23.14M	261.06M	163.10M
	Stockholders Equity
83.61M	22.89M	95.71M	202.22M	-95.72M	-59.53M
Cash Flow		Free Cash Flow
-18.04M	-31.50M	-77.03M	-83.12M	-33.96M	-18.32M
	Operating Cash Flow
-18.05M	-31.50M	-74.85M	-67.13M	-31.33M	-17.32M
	Investing Cash Flow
71.00K	1.33M	-2.18M	-15.92M	-2.63M	-973.00K
	Financing Cash Flow
0.00	-16.16M	14.87M	119.11M	91.47M	53.30M

Finch Therapeutics Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FNCH, the sentiment is Negative. The current price of 12.4 is below the 20-day moving average (MA) of 13.66, below the 50-day MA of 14.10, and above the 200-day MA of 10.65, indicating a neutral trend. The MACD of -0.37 indicates Positive momentum. The RSI at 30.90 is Neutral, neither overbought nor oversold. The STOCH value of 10.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FNCH.

Finch Therapeutics Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.36B	1.19	-46.31%	2.67%	19.41%	1.23%
SYBX	45 Neutral	$11.99M	―	-109.67%	―	-99.76%	76.96%
MCRB	44 Neutral	$102.96M	―	-3758.21%	―	-100.00%	-7.66%
FNCH	42 Neutral	$19.91M	―	-326.64%	―	-100.00%	89.80%
ADIL	40 Underperform	$4.67M	―	-323.80%	―	―	45.99%
SLDB	35 Underperform	$209.23M	―	-94.57%	―	―	37.17%